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 FOREWORD 
 
The Trent  Working Group on Acute Purchasing was set up to enable purchasers to share 
research knowledge about the effectiveness and cost-effectiveness of acute service 
interventions and determine collectively their purchasing policy. The Group is facilitated by 
The School of Health and Related Research (ScHARR), part of the Trent Institute for Health 
Services Research, the ScHARR Support Team being led by Professor Ron Akehurst and 
Dr Nick Payne, Consultant Senior Lecturer in Public Health Medicine. 
 
The process employed operates as follows. A list of topics for consideration by the Group is 
recommended by the purchasing authorities in Trent and approved by the Health Authority 
and Trust Chief Executives (HATCH) and the Trent Development and Evaluation Committee 
(DEC). A public health consultant from a purchasing authority leads on each topic assisted 
by a support team from ScHARR, which provides help including literature searching, health 
economics and modelling. A seminar is led by the public health consultant on the particular 
intervention where purchasers and provider clinicians consider research evidence and agree 
provisional recommendations on purchasing policy. The guidance emanating from the 
seminars is reflected in this series of Guidance Notes which have been reviewed by the 
Trent DEC, chaired by Professor Sir David Hull. 
 
In order to share this work on reviewing the effectiveness and cost-effectiveness of clinical 
interventions, The Trent Institute’s Working Group on Acute Purchasing has joined a wider 
collaboration, InterDEC, with units in other regions. These are: The Wessex Institute for 
Health Research and Development and The University of Birmingham Department of Public 
Health and Epidemiology. 
 
 
 
 
 
 
 
Professor R L Akehurst, 
Chairman, Trent Working Group on Acute Purchasing 
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EXECUTIVE SUMMARY 
 
The purpose of giving routine antenatal anti-D prophylaxis (AADP) is to prevent cases of 
haemolytic disease of the new-born (HDN). These can occur when a woman whose blood 
group is RhD negative develops antibodies against the red blood cells of her RhD positive 
fetus. Although this is unlikely to cause harm during that pregnancy, any subsequent 
pregnancy with a RhD positive fetus will be at risk of HDN. The possible consequences of 
HDN include anaemia, jaundice, brain damage and death. Management of a pregnancy in a 
woman with anti-D antibodies requires intensive monitoring and may involve interventions 
such as fetal blood sampling, exchange transfusion and neonatal intensive care. 
 
The production of anti-D antibodies by the mother can be prevented by injecting anti-D 
obtained from human donors. Over 90% of cases of HDN have been prevented by the 
widespread use of postnatal anti-D prophylaxis (for all RhD negative women who deliver a 
RhD positive infant) and of antenatal anti-D prophylaxis in defined circumstances, such as, 
miscarriage or abdominal trauma. Despite these measures, about 1.5% of RhD negative 
women will still have developed anti-D antibodies following a RhD positive pregnancy. Meta-
analysis of the nine relevant published studies provides strong evidence that the 
sensitisation rate can be reduced to about 0.24% by giving AADP routinely to RhD negative 
women during the third trimester. The preferred dose regime is one dose of anti-D at 28 
weeks gestation and a second at 34 weeks. 
 
Anti-D Immunoglobulin (IgG) is a human plasma-based product and so, naturally, there is 
concern over its safety. Intramuscular immunoglobulins, which include anti-D, have an 
excellent safety record with no reported cases of viral transmission. Moreover, the available 
products are produced from non-UK donor plasma and the Medicines Control Agency has 
recommended these for antenatal prophylaxis. Patients and staff ought already to be 
receiving suitable information about the safety of anti-D IgG, as postnatal anti-D prophylaxis 
is a routine procedure. 
 
This report identifies the costs, clinical consequences and cost-effectiveness of the three 
main options for purchasers: 
 Option 1 - not offering routine AAPD; 
 Option 2 - offering routine AADP to RhD negative primigravidae only; 
 Option 3 - offering routine AADP to all RhD negative women. 
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For a ‘typical’ district of 500,000 population, Option 2 would cost approximately £12,100 per 
year, with cost effectiveness ratios of £3,800 per case of Rhesus disease prevented, £5,200 
per Life Year Gained (LYG), or £85,300 per fetal loss avoided. Option 3 would cost 
approximately £33,000 per year, with cost-effectiveness ratios of £6,400 per case of Rhesus 
disease prevented, £9,700 per LYG, or £159,400 per fetal loss avoided. 
 
Option 2 has a lower gross cost and is marginally more cost-effective in comparison to 
option 3. However, practical and ethical difficulties are foreseen in implementing option 2, 
and so, since option 3 is cost-effective in comparison with many other health care 
interventions provided by the NHS, this is the preferred option. 
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1. INTRODUCTION 
 
1.1 Incidence and Pathology 
 
Haemolytic Disease of the New-born (HDN) is a haemolytic anaemia affecting the fetus or 
neonate and resulting from the transplacental passage of maternal allo-antibodies directed 
against fetal red cell antigens inherited from the father. Over 90% of all cases of clinically 
significant HDN affect Rhesus D (RhD) positive infants born to RhD negative mothers. The 
mothers usually make the anti-D antibody following a small foeto-maternal haemorrhage at 
delivery of the first RhD positive infant. This does not harm the current infant, but successive 
RhD positive infants are then progressively more severely affected by HDN. Maternal 
sensitisation can also result from the transfusion of RhD positive red cells. 
 
Approximately 17% of women are RhD negative and in about 10% of all pregnancies the 
mother is RhD negative and the fetus RhD positive. It is during these pregnancies that the 
mother is at risk of becoming sensitised. Prior to the introduction of any immunoprophylaxis, 
the frequency of the disease was one per 100 births in second pregnancies and higher in 
subsequent pregnancies. In the mid 1950s in England and Wales, HDN was responsible for 
310 deaths per year - one in 2,180 births.  
 
Since that time prophylaxis with anti-D and advances in neonatal care alone have had a 
major impact. Standard anti-D prophylaxis was introduced in the UK in 1969 and by 1989 
the comparable registered death rate was 1 in 65,000 births. Such registrations should be 
considered an underestimate because fetal loss before 28 weeks, including death due to 
severe hydrops for example, was not registrable. 
 
In the UK, conventional practice is to give intravenous anti-D immunoglobulin within 72 
hours of delivery to all RhD negative women who have RhD positive infants and are not 
already sensitised. The size of any foeto-maternal bleed is estimated and a further anti-D 
dose given if indicated. Any event during pregnancy with the potential to cause sensitisation 
should also prompt an anti-D injection within 72 hours. Such events include abdominal 
trauma, miscarriage, amniocentesis, chorion villous sampling, antepartum haemorrhage, 
external cephalic version and termination of pregnancy. 
 
Despite this policy, however, there is a failure rate resulting in sensitisation prior to delivery 
of the first pregnancy. These failures have been examined and a proportion found due to 
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failure to adhere to the existing policy, through lack of administration of  (a) any anti-D, (b) 
enough anti-D or (c) timely anti-D when clearly indicated. Even after allowing for these 
failures, there remains a significant number of women who develop ‘silent’ sensitisation in 
the absence of any identifiable risk event and for whom post delivery prophylaxis is too late. 
These are the women who stand to benefit from routine antenatal anti-D prophylaxis 
(AADP). From the studies reviewed in this Guidance Note, it appears that approximately 
1.5% of RhD negative women with RhD positive infants develop ‘silent’ sensitisation. It 
should also be noted that women who experience ‘silent’ sensitisation appear to be high 
responders who suffer a higher rate of fetal morbidity and mortality due to HDN and, 
consequently, require the highly specialised support services. 
 
1.2 Prognosis 
 
The severity of disease seen in the infant varies according to certain properties of the 
antibody, its level and the duration of exposure of the infant to that level. Thus, affected 
pregnancies require close monitoring of both the maternal antibody level (every two weeks 
from 20 weeks) and the state of the fetus by ultrasound, amniocentesis and periumbilical 
blood sampling, if indicated. The maternal antibody ‘coats’ or sensitises the infant’s red cells 
provoking their premature clearance from the circulation and resulting in anaemia and 
jaundice. In utero, fetal bilirubin crosses the placenta and is cleared by the maternal 
circulation. After delivery, however, clearance is dependent on the immature neonatal liver 
and unconjugated bilirubin accumulates. 
 
In its mildest form the sensitised red cells are detectable in laboratory tests alone, but more 
commonly the infant has a mild degree of jaundice which responds to phototherapy. More 
severe degrees involve significant anaemia and progressive hyperbilirubinaemia. Certain 
neonatal brain structures, e.g. thalamus, corpus striatum, are particularly sensitive to 
damage by unconjugated bilirubin. The resulting clinical condition - kernicterus - has severe 
manifestations with physical disabilities and often mental retardation. In its most severe form 
the in utero anaemia causes cardiac failure, hydrops and intrauterine death. 
 
The benefits of close monitoring of bilirubin levels and the ability of exchange transfusion to 
correct both anaemia and hyperbilirubinaemia should make kernicterus a thing of the past. 
The introduction of periumbilical blood sampling in the early 1980s and the ability to 
establish fetal RhD type and Haemoglobin (Hb) level has eased the management of 
potentially severely affected infants, not least by providing a return route for direct 
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intravascular intrauterine transfusion (IUT). This has led to a major reduction in the need for 
elective premature delivery (e.g. at 28 weeks) and the resulting risks. It has to be balanced, 
however, against an estimated 5% fetal loss from IUT. Such intervention requires a highly 
specialised unit with skilled personnel, equipment (particularly radiological) and access to 
specialised blood products. 
 
1.3 Scale of Problem in a ‘Typical’ District 
 
The crude rate for all births is 12.5 per 1,000 population of all ages per annum, figures 
taken from the 1996 Birth Statistics, England and Wales – Office of National Statistics 
(ONS).
1
 Therefore, in a ‘typical’ district of 500,000 population there are approximately 6,250 
deliveries a year, 17% of which are in RhD negative women, i.e. 1,062 deliveries, and RhD 
negative women with a RhD positive baby account for 10% of deliveries, i.e. 625 per annum.  
 
Assuming that 1.5% of RhD negative women with a RhD positive baby become sensitised 
antenatally, approximately nine women become sensitised per year. Eight of these women 
are likely to have a subsequent pregnancy, which will have to be closely monitored and in 
which HDN may occur. The cost of this monitoring and treatment is approximately £1,320 
per case. Of these eight subsequent pregnancies, six fetuses are likely to develop Rhesus 
disease and one fetus is likely to be lost every five years. The net cost of treating nine 
sensitised women and the subsequent complications, i.e. cases of Rhesus disease, is 
estimated between £8,991 and £11,401. 
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2. USE OF ROUTINE ANTENATAL ANTI-D PROPHYLAXIS FOR RHESUS  
 NEGATIVE WOMEN : SUMMARY OF EVIDENCE OF EFFECTIVENESS 
 
2.1 Evidence of Effectiveness 
 
2.1.1 Reduction in the Rate of Rhesus Sensitisation Attributable to Antenatal anti-D 
Prophylaxis 
 
Trials of the effectiveness of Antenatal anti-D Prophylaxis (AADP) were identified through 
searching Medline, Embase, the Cochrane Database of Systematic Reviews, conference 
reports and reference lists. Nine relevant studies were identified, published between 1978 
and 1995, of which six were non-randomised trials with historical or geographical 
controls,
2,3,4,5,6,7
 two were randomised controlled trials,
8,9
 and one was a population-based 
before-and-after study.
10
 Because only one of the randomised controlled trials used a 
dosage regime which is currently considered appropriate,
8
 the non-randomised studies have 
been retained for further consideration here. 
 
The patient selection criteria and the dosage regimes used vary between the nine studies. In 
four studies AADP was given to primigravidae only,
2,7,9,10
 though the results from one of 
these studies relate to both primigravidae who received prophylaxis and multigravidae who 
did not.
10
 In the remaining five studies AADP was given to both primigravidae and 
multigravidae;
3,4,5,6,8
 results for the sub-group of primigravidae were reported separately in 
one of these.
8
 The dose of anti-D used varies six-fold between the studies, from two doses 
of 1,500 international units (iu) down to two doses of 250 iu. The two most widely used 
dosage regimes are 500 iu at 28 and 34 weeks gestation, and a single dose of 1,500 iu at 
28 weeks. 
 
In the nine trials, a total of 17,398 RhD negative women who bore RhD positive babies were 
given AADP and observed during the trials. Of these, 48 became sensitised. A total of 
11,757 women at risk of Rhesus sensitisation were studied as control groups, of which 174 
became immunised. The largest study
4
 accounts for over half of the total number of 
intervention patients in the literature, but the design of this study is relatively weak: the 
intervention group received AADP between 1977 and 1986, but the results were compared 
with the experience of controls from the same geographical area during the period 1967 - 
1974. The results are shown in Table 1. All the sensitisation rates relate to women at risk of 
Rhesus sensitisation i.e. RhD negative women who are pregnant with a RhD positive baby. 
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Table 1 Summary of Trial Results 
 
Study 
 
Study 
Design 
 
Dosage 
 
Patient 
Selection 
n r % 
Sensitised 
in anti-D 
Prophylaxis 
Group 
Upper 
95% CI 
Lower 
95% CI 
n r % 
Sensitised 
in Control 
Group 
Upper 
95% CI 
Lower 
95% CI 
Bowman
2
 
(1978) 
NRCT 2 x 1500iu 
(28 and 34 
weeks) 
Primigravidae 1,357 1 0.07 0.22 0.00 2,768 45 1.63 2.10 1.15 
Bowman
3
 
(1978) 
NRCT 1 x 1500iu 
(28 weeks) 
Unselected 1,805 5 0.28 0.52 0.03 3,533 62 1.75 2.19 1.32 
Bowman
4
 
(1987) 
NRCT 1 x 1500iu 
(28 weeks) 
Unselected 9,295 25 0.27 0.37 0.16 3,533 62 1.75 2.19 1.32 
Trolle
5
 
(1989) 
NRCT 1 x 1500iu 
(28 weeks) 
Unselected 291 0 0.00 0.00 0.00 322 6 1.86 3.34 0.39 
Hermann
6
 
(1984) 
NRCT 1 x 1250iu 
(34 weeks) 
Unselected 529 2 0.38 0.90 0.00 645 10 1.55 2.50 0.60 
Tovey
7
 
(1983) 
NRCT 2 x 500iu Primigravidae 1,238 4 0.32 0.64 0.01 2,000 19 0.95 1.38 0.52 
Huchet
8
 
(1987) 
RCT 2 x 500iu (28 
and 34 
weeks) 
Primigravidae 
Multigravidae 
Unselected 
362 
110 
472 
0 
1 
1 
0.00 
0.91 
0.21 
0.00 
2.68 
0.63 
0.00 
0.00 
0.00 
360 
108 
468 
4 
3 
7 
1.11 
2.78 
1.50 
2.19 
5.88 
2.60 
0.03 
-0.32 
0.40 
Lee
9
  
(1995) 
RCT 2 x 250iu  
(28 and 34 
weeks) 
Primigravidae 513 4 0.78 1.54 0.02 595 9 1.51 2.49 0.53 
Mayne
10
  
(S. Derbyshire) 
(1997) 
Before 
and 
After 
2 x 500iu (28 
and 34 
weeks) 
Unselected 1,898 6 0.32 0.57 0.06 1,426 16 1.12 1.67 0.58 
Key : 
 NRCT = non randomised controlled trial 
 RCT = randomised controlled trial 
 n = number of Rhesus negative women with Rhesus positive babies in the trial group 
 r = number of sensitised Rhesus negative women in the trial group 
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2.1.2 Meta-Analysis 
 
The variability in study design, randomisation and control design, patient selection criteria, 
primigravidae only or all women, and dosage regimes makes meta-analysis problematic. 
This report presents three meta-analyses: 
 
 Group 1 includes the results of the two studies
7,8
 (one randomised, one not) which used 
a dosage regime of 500 iu at 28 and 34 weeks and report results for primigravidae; 
 Group 2 includes the results of the three studies,
3,4,5
 (none of them randomised) which 
used a dosage regime of 1,500 iu at 28 weeks and included both primigravidae and 
multigravidae; 
 Group 3 includes the results of all the identified studies except the trial by Lee (1995)
9
 
which was omitted as the dosage regime consisted of two injections of 250 iu anti-D 
Immunoglobulin (IgG), which is now considered to be too low. 
 
The method of meta-analysis performed on the three groups of trials was a binary logistic 
regression on a fixed-effects model.
11
 The study and treatment group were the variables in 
the model and the effect size was measured as an odds ratio. As the event rate is low, the 
odds ratio is a good approximation of the relative risk of sensitisation in the cohort which 
received antenatal prophylaxis, compared with that in the group which received no 
treatment. To test for heterogeneity, an interaction term between the study and treatment 
variables was added. This was not statistically significant and, therefore, indicated that there 
was no evidence to reject the hypothesis of homogeneity between the trials grouped for 
meta-analysis, 
2
 = 1.043 on 1 df,  p = 0.31, 
2
 = 0.77 on 1 df, p = 0.38 and 
2
 = 3.62 on 6 
df, p = 0.73 for the three meta-analyses respectively.  Furthermore, visual examination of 
the absolute results in the treatment and no treatment groups, and the odds ratio for all the 
studies, see figures 1-3, show a remarkable consistency in results. 
 
The sensitisation rate for the group who received no treatment was calculated by taking the 
average of the sensitisation probabilities, estimated from the logistic regression model 
applied to each study. As the control group used in the Bowman 1987 study
4
 was the control 
group of the Bowman 1978 study
3
, the two trials were combined into one three armed study 
in the meta-analysis in order to prevent the control group being double counted. The results 
of the meta-analyses are in Table 2 . 
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Table 2 Results of the Meta-analyses 
 Group 1 - 2x500iu 
Primigravidae 
Group 2 - 1x1500iu 
Primigravidae and 
Multigravidae 
Group 3 - All 
Trials except 
the  2 x 250iu 
Trial 
Test for Heterogeneity        
(p-value) 
0.31 0.38  0.73 
Odds Ratio of Sensitisation 
with Antenatal Prophylaxis 
0.26 0.15 0.16 
95% CI (0.09; 0.75) (0.09 ; 0.23) (0.11 ; 0.23) 
Sensitisation Rate of 
Control Group 
0.94% 1.71% 1.47% 
95% CI (0.83%; 1.04%) (1.58% ; 1.84%) (1.30% ; 1.65%) 
Sensitisation Rate of 
Antenatal Prophylaxis 
Group using Meta-analysis 
0.24% 0.26% 0.24% 
Range (0.09%; 0.62%) (0.17% ; 0.36%) (0.18% ; 0.30%) 
 
 
Figure 1 Meta-analysis of Group 1 
  2 x 500 iu in Rhesus Negative Primigravidae 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Odds Ratio = 0.26 
95% confidence Intervals = (0.09 ; 0.75) 
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Figure 2 Meta-analysis of Group 2 
1 x 1,500 iu in Unselected Rhesus Negative Women  
 
 
 
 
 
 
 
 
 
 
 
 
Odds Ratio = 0.15 
95% Confidence Interval = (0.09 ; 0.23) 
 
Figure 3 Meta-analysis of Group 3 
  All Trials of Dose Regimes Currently Considered to be Effective 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Odds Ratio = 0.16 95%  
Confidence Interval = (0.11 ; 0.23) 
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In all three meta-analyses AADP produced a significant reduction in the rate of Rhesus 
sensitisation. The summary odds ratio for the 2 x 500 iu dose regime (0.26) is higher than 
that for the 1 x 1,500 iu regime (0.15). However, the confidence intervals of these odds 
ratios overlap widely. Figure 3 shows that the results of the non-randomised studies are very 
similar to those of the one randomised study which used a currently recommended dose of 
anti-D.
8
 This suggests that the non-randomised studies are unlikely to be seriously biased.  
 
In order to assess the possibility of publication bias, a funnel plot is presented in Figure 4. In 
the  absence of publication bias, because of sampling variability, the graph should have the 
shape of an upside down funnel, with the large opening down and the tip pointing up and 
centred on the true effect size. This can be seen to be the case in Figure 4.  Publication bias 
would result in the funnel being skewed either to the left, positive bias, or to the right, 
negative bias. 
 
Figure 4 Assessing the Possibility of Publication Bias 
0
2000
4000
6000
8000
10000
12000
14000
0.0100 0.1000 1.0000
Odds Ratio
No Effect
Increase in Effect
 
 
The odds ratio for the randomised trial of 2 x 250 iu 
9
 was 0.51 (95% CI 0.16 -1.67). This is 
considerably higher than the summary relative risks from each of the meta-analysis groups. 
No Effect Increase in Effect 
 12 
The trial itself concluded that two doses of 250 iu were not as effective as either of the 
higher dosage regimes and could not be recommended for routine prophylaxis. 
 
In the absence of any firm evidence to the contrary, this report assumes that there is no 
difference in effectiveness between any of the dose regimes assessed except for the 2 x  
250 iu regime, which appears to be less effective. (It is acknowledged that when the 1 x  
1,500 iu at 28 weeks regime has been used, about 30% of women have required a further 
dose at 36 weeks).
2
  In order to use the greatest possible amount of trial data consistent 
with this assumption, the subsequent analyses in this report use the results of the third 
meta-analysis, that is, it incorporates in a single estimate the results of all the trials of dose 
regimes that are currently considered to be effective. 
 
2.1.3 Reduction in the rate of fetal loss attributable to antenatal prophylaxis 
 
Fetal loss due to Rhesus disease has become a relatively rare event since the widespread 
introduction of postnatal anti-D prophylaxis. It was, therefore, not used as an outcome 
measure in any of the trials of effectiveness of AADP. The rate of sensitisation has been 
used as an intermediate endpoint and is assumed to be directly related to fetal loss rates. In 
order to estimate the potential reduction in the rate of fetal loss attributable to a policy of 
routine antenatal prophylaxis the following steps have been taken: 
 
 the rate of fetal loss over a defined time period is obtained; 
 it is assumed that the no treatment polices represented in the control arms of the studies 
typify practice in the UK over the above period, and that, therefore, the sensitisation rate 
of 1.5% can be related to the underlying fetal loss rate; 
 it is further assumed that a reduction in the sensitisation rate will lead to proportionate 
reduction in the prevalence of sensitisation, HDN and fetal loss. 
 
From 1977 to 1989 all deaths registered as due to haemolytic disease of the new-born 
(HDN) in England and Wales have been analysed by individual case note review.
12,13
 In 
order to be registered as a death during that period a baby had to be either stillborn, that is 
at least 28 weeks’ gestation, by definition, or born alive at any gestation, including a 
proportion below 28 weeks’ gestation. The published analysis used six categories to classify 
the likely cause of the haemolytic disease: 
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1. Mother believed to have been immunised by a pregnancy following which she was not 
given anti-D. 
2. Mother immunised during first pregnancy. 
3. Mother immunised despite having been given anti-D after one or more previous 
pregnancies. 
4. Mother immunised to D by blood transfusion. 
5. Haemolytic disease due to an antibody other than anti-D. 
6. Death not due to haemolytic disease. 
 
The deaths which are potentially preventable by AADP are those in categories 2 and 3. Over 
the period 1977 to 1989 there were 195 deaths in these two categories, an average of 15 
per year. This equates to a rate of loss of 0.02% among RhD negative women with a RhD 
positive baby, assuming that they constituted 10% of all births during this period. This rate 
does not include fetal losses that occurred prior to 28 weeks’ gestation, unless the fetus was 
born alive. A review of fetal losses due to haemolytic disease at one tertiary referral centre 
in Glasgow over a 15 year period found that 21 out of 46 losses (46%) occurred before 28 
weeks’ gestation.
14
 Therefore, taking the rate of fetal loss before 28 weeks’ gestation to be 
half of the total loss, the rate of loss among RhD negative women with a RhD positive baby 
would be 0.04%. 
  
More recently, the Trent Confidential Enquiry into Stillbirths and Deaths in Infancy (CESDI) 
report
15
 includes data regarding cause of death for late fetal losses (defined as 20-23 
weeks’ gestation), stillbirths and infant deaths in England, Wales and Northern Ireland. In 
1995, 14 such deaths were attributed to Rhesus disease, out of a total of 676,737 late fetal 
losses, still and live births. If one assumes that 10% of these were accounted for by RhD 
negative women with RhD positive babies, this represents a rate of loss of 0.02%. Since a 
detailed analysis of the proportion of these deaths which might have been prevented by 
antenatal AADP is not available, this figure includes an uncertain proportion of losses which 
will have been due to failures of postnatal prophylaxis or sensitisation following blood 
transfusion. No information is available regarding the distribution of these losses before and 
after 28 weeks’ gestation.  
 
2.2 Effective Antenatal Dose Regimes 
 
There are two anti-D products licensed for AADP in the UK.  One, produced by Bio Products 
Laboratory (BPL), is a 500 iu dose and the other, produced by Baxter Healthcare, is a 1,250 
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iu dose, ‘Partobulin’.  Both product licenses are for a two injection regime at 28 and 34 
weeks. 
 
There is evidence of the efficacy of a single dose of 1,500 iu at 28 weeks, but this product is 
not available in the UK. In addition, there appear to be a significant number of women who 
require a further injection in order to maintain an adequate protective anti-D level until 
delivery. 
 
There is no available evidence for the efficacy of a single injection of 1,250 iu at 28 weeks, 
nor of its ability to  maintain a protective level until delivery. Theoretical calculations based 
on the half-life of IgG suggest that this may be inadequate. Moreover, such use of 
Partobulin is outside the terms of its Product Licence. 
 
For these reasons the remainder of this report considers the 28 and 34 week regime only. 
Such AADP is given to all RhD negative women.  Those (~60%) who subsequently have a 
RhD positive infant must be given further standard post-delivery prophylaxis.  This need is 
not replaced by routine AADP. 
 
2.3 Safety of Anti-D Immunoglobulin 
 
For the Infant 
There is no evidence that anti-D given to the mother during pregnancy is harmful to the 
infant, even when repeated large doses are given. A minority (<10%) of infants will be found 
to have laboratory evidence of red cell sensitisation but this is sub-clinical and does not 
result in anaemia, jaundice or the need for phototherapy. 
 
For the Mother 
The only source of therapeutic IgG is human plasma. Monoclonal anti-D is under 
development, but remains several years away from routine use. Intramuscular 
immunoglobulins, which include anti-D, have an excellent safety record which extends prior 
to the introduction of specific virology testing of donors and viral inactivation of the end 
product. There have been no reported cases of viral transmission from either product 
licensed in the UK. Safety starts with correct donor selection and anti-D donors are the most 
committed, highly selected and frequently tested of all blood donors. Each donation is 
screened for Hepatitis B, Hepatitis C, HIV 1 and 2 and Syphilis. There was a report of 
Hepatitis C transmission by IgG in Ireland in the early 1990s, but this involved an 
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intravenous product and significant concerns were raised about the manufacturing system. 
Moreover, intramuscular immunoglobulins have always had a better safety profile than when 
used intravenously. 
 
As with other human-derived blood products, the risk of new variant CJD (nvCJD) 
transmission is unknown. BPL, the UK manufacturer of the 500 iu product, is in the process 
of switching its production from UK to North American plasma. Until this has been 
completed, due to a recommendation by the Department of Health (DoH) and in consultation 
with the Medicines Control Agency (MCA), BPL has removed the use of anti-D for antenatal 
prophylaxis as one of the licensed indications for this product. This change does not imply 
that there has been any new information which makes the risk of transmission of nvCJD 
from blood products anything more than ‘theoretical’ and this measure is purely 
precautionary. BPL believes that anti-D manufactured from US plasma will be available by 
mid-1999. 
 
The use of UK derived IgG for routine conventional practice is still licensed as there is a 
known higher risk of HDN if IgG is not administered at the appropriate time. 
 
The recommendation by the MCA for this change in use of anti-D from UK plasma has 
occured as it was considered that since antenatal prophylaxis involved exposure of two 
people to the unknown risks of nvCJD (the pregnant woman and her unborn baby), it would 
be preferable to delay introduction of the guidelines until a certain supply of product 
manufactured from outside the UK was available. The MCA feels that this is a temporary 
issue and, as soon as an adequate supply of non-UK anti-D is available, universal routine 
antenatal prophylaxis can be recommended.
16
 There is, at present, a licensed product, 
Partobulin, which is manufactured from non-UK plasma and for which the indications of 
routine antenatal prophylaxis are retained. 
 
Baxter Healthcare, the manufacturer of Partobulin, the only currently UK-licensed product 
(1,250 iu), declined to be specific about the source of its anti-D plasma, but stated that 
donor plasma for its range of products was collected in the USA, Austria, Germany and 
Sweden. 
 
As anti-D IgG is a human plasma-based product there is, naturally, public concern over its 
safety. However, as anti-D IgG is given to all Rhesus negative mothers who give birth to a 
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Rhesus positive infant as a routine procedure, all patients and staff should already be 
receiving suitable information about the product. 
 
Anti-D Immunoglobulin supply position 
At the time of writing, BPL has given assurance of its ability to meet the increased demand 
for the product consequent on the introduction of routine AADP.  However, Baxter 
Healthcare  said it was not in a position to supply the product in addition to existing contracts 
for conventional prophylaxis. 
 
2.4 Conclusion on Direction of Evidence and its Quality 
 
The various studies, covering different patient groups and different treatment regimes, all 
have remarkably consistent results in terms of risk reduction. The 95% CI for the 
sensitisation rates for all trials overlap, indicating that there are no significant differences 
between the results of any of the trials. Furthermore, tests for heterogeneity between the 
studies are negative and visual inspection of the results shows similar conclusions. Although 
most of the studies are non-randomised, their results are very similar to those of the one 
randomised controlled trial of a current dosage regime. The studies provide strong evidence 
that routine AADP reduces the risk of antenatal sensitisation by approximately 80%. 
 
The rate of fetal loss due to antenatal sensitisation and, consequently, the mortality benefit 
from a reduced sensitisation rate is more difficult to determine. Published studies indicate 
that, over a period prior to the widespread introduction of routine AADP, the fetal loss rate 
was approximately 0.04% of all RhD negative women with RhD positive fetuses. 
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3. COST AND BENEFIT IMPLICATIONS OF ADOPTING INTERVENTION 
 
The aim of this section is to evaluate the health service cost and cost-effectiveness of 
providing routine AADP for RhD negative pregnancies. There are several possible options 
for implementing a programme of prophylaxis. This evaluation considers the following: 
Treatment groups: 
 providing AADP for all RhD negative pregnancies; 
 providing AADP only to RhD negative primigravidae; 
Dosage regime: 
 providing treatment consisting of two 500 iu injections of anti-D IgG, one at 28 weeks 
and the second at 34 weeks. 
 
The costs and benefits associated with each treatment group are evaluated in comparison 
to conventional management of RhD negative pregnancies, which is defined as: 
 anti-D prophylaxis given within 72 hours of identified potentially sensitising events, such 
as, abdominal trauma etc; 
 postnatal anti-D IgG given within 72 hours of delivery to all RhD negative women who 
have RhD positive infants and are not already sensitised. 
 
No statistically significant difference in effectiveness between any of the dose regimes 
assessed has been identified, except for the 2 x 250 iu regime. Therefore, as discussed in 
Section 2.2, the results from the meta-analysis of all acceptable studies, have been used to 
evaluate the cost-effectiveness of all dose regimes of AADP.  
 
Furthermore, since there is no evidence of a differential effectiveness between a 2 x 500 iu 
regime and a 2 x 1,250 iu regime, it can be inferred that the relative cost-effectiveness will 
purely depend on the difference in anti-D IgG costs. 
 
 18 
3.1 The Costs of Routine Antenatal Prophylaxis 
 
This evaluation takes a health service perspective of costs; indirect and societal costs have 
not been considered. The effect of discounting future costs and future benefits is explored 
over a range of rates varying between 0% and 10%, with a central estimate of 6%. 
 
The costs incurred through providing AADP are the cost of the anti-D IgG and the cost of 
the administration of the treatment. The economic benefits from the programme are the 
direct savings due to the avoidance of additional treatment costs, which would have been 
incurred as a result of a subsequent pregnancy in a sensitised woman. 
 
The cost of a 500 iu vial of anti-D IgG is £16.43 (BPL). Therefore, the cost of providing the 
lower dose regime is £32.86 per woman at risk. The cost of a 1,250 iu vial of anti-D IgG is 
£15.90 (Baxter Healthcare). Consequently, the cost of the higher dose regime is £31.80 per 
woman at risk. As there is very little information on the 1,250 iu dose, it is assumed that the 
protection of the 2 x 1,250 iu dose is the same as the 2 x 500 iu and 2 x 1,500 iu regime.   
 
It is envisaged that the anti-D injections can be administered by a midwife during a normal 
routine antenatal visit. Therefore, the logistic cost of implementing the policy has been 
estimated at £5 per RhD negative woman treated.  
 
The gross annual cost of undertaking routine AADP in a ‘typical’ district of 500,000 
population would be approximately £34,900 for the 2 x 500 iu regime and £33,800 for the 2 
x 1,250 iu dose when treating all RhD negative women. 
 
The direct savings due to the prevention of sensitisation are estimated at £1,320 per 
affected pregnancy avoided, i.e. sensitised in the previous pregnancy and pregnant with 
another child. This cost includes a longer and more intensive hospital stay for the baby, 
costs for amniocenteses, fetal blood sampling, neonatal follow-up visits, possible 
Intrauterine Transfusion (IUT), phototherapy and exchange transfers. These costs are taken 
from the Oxford RHA in 1996 and are shown in Table 3 as they were published in the report 
‘Building on Success: Antenatal Prophylaxis’.
17
 The costs are likely to represent an 
underestimate of the true savings as they do not include a longer hospital stay for the 
mother, the cost of a greater number of caesarean sections and induction of labour, and the 
possibility of problems in future pregnancies. 
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The median length of time between the birth of the first and second child is 35 months (all 
women in Great Britain).
15
 The intervals from second to third birth and between third and 
fourth are also of a similar magnitude. As the savings from the programme are due to the 
avoidance of additional treatment costs which would have been incurred as a result of a 
subsequent pregnancy in a sensitised woman, the value of the savings have been 
discounted at 6% for three years. This results in the current value of the savings being 
estimated at £1,108. 
 
The cost of caring for infants with a long-term disability resulting from Rhesus disease has 
not been included in this analysis. Severe disability due to Rhesus disease is now rare, but 
several papers have reported instances of extreme handicap resulting from IUT, with rates 
of up to 10%.
18,19,20
 The lifetime cost of caring for a disabled child is enormous. A paper by 
Stevenson et al.
21
 on the cost of care of disabled low birthweight infants to the age eight - 
nine years quotes a figure of £6,926 per disabled low birthweight child compared with 
£4,027 for a non-disabled low birthweight child, with costs discounted and expressed in 
1979 prices. This cost includes neonatal care, health service use, special education and 
institutional care. The paper continues, using the assumption that a non-disabled low 
birthweight child will impose no extra cost on the exchequer after age nine, and will receive 
mainstream education to age 18, to estimate a lifetime cost of disability to be £69,597 per 
disabled child. Therefore, the prevention of sensitisation could not only prevent the birth of a 
disabled infant but also all the associated costs of care.  
 
This estimate of the savings achieved through preventing anti-D sensitisations is 
substantially lower than that produced by a team in Aberdeen.
22
 They estimated that £2,164 
would be saved during the current pregnancy (i.e. the pregnancy during which sensitisation 
would occur in the absence of AADP), and a further £2,262 in future pregnancies. Since 
sensitisation is very unlikely to cause clinical harm during the current pregnancy, it has been 
assumed that AADP would not produce any savings until future pregnancies. Comparison of 
methods used may enable a reconciliation of the difference between these estimates of 
savings in future pregnancies (£1,320 v. £2,262). The authors aim to clarify these issues 
with the Aberdeen team, but have yet to receive a response to their enquiries. 
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Table 3 Cost of Treating 100 Pregnancies in Sensitised Women (After Selinger)
17
 
 
Number of new cases with immunisation per year   100 
  No. of cases requiring intensive antibody monitoring (A)   90 
  No. of cases severe enough to require fetal assessment/treatment   10 
 No. of cases undergoing serial fetal blood sampling (B)   5 
 No. of cases undergoing serial intrauterine transfusion (C)   5 
 No. of cases requiring neonatal care only (D)   10 
Cost of A   
 5 antenatal serology investigations + management in 90 cases  £22,500 
 Sub total A £22,500 
Cost of B   
 5 cases requiring 3 fetal blood sampling + 5 days high-
dependency neonatal unit = 5 x [(3 x £500) + ( 5 x £800)] 
 £27,500 
 5 cases requiring 2 neonatal follow-up visits = 5 x £100  £500 
 Sub total B £28,000 
Cost of C   
 5 cases requiring 3 intrauterine transfusions + 3 days 
intensive care neonatal unit + 5 days high-dependency 
neonatal unit = 5 x [(3 x £1200) + (3 x £1200) + (5 x £800)] 
 £56,000 
 5 cases requiring 2 neonatal follow-up visits = 5 x £100  £500 
 Sub total C £56,500 
Cost of D   
 10 cases requiring phototherapy / exchange transfer only    = 
10 x (3 x £800) 
 £24,000 
 10 cases requiring 2 neonatal follow-up visits = 10 x £100  £1,000 
 Sub total D £25,000 
Cost per 100 Rhesus negative pregnant women, sensitised 
in a previous pregnancy.  
 
Total 
A+B+C+D 
 
 
 
£132,000 
 
3.2 Cost-effectiveness 
 
A range of cost-effectiveness outcomes is calculated; cost per sensitisation prevented, cost 
per case of Rhesus disease prevented, cost per fetal loss avoided and cost per life year 
gained (LYG). The intermediate outcome, cost per sensitisation avoided, is included as this 
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can be estimated directly from the study evidence with a high degree of certainty and allows 
comparison with other health economic studies. The measures of cost per fetal loss avoided 
and cost per LYG have been included in order to provide a comparison of cost-effectiveness 
with other health care interventions. However, it should be noted that these are based upon 
an assumed relationship between reduced sensitisation and fetal loss rates. 
 
Furthermore, there is an issue of quality of life for babies born with Rhesus disease, as 
several papers have reported instances of severe handicap resulting from IUT, with rates of 
up to 10%.
18,19,20
 Also the quality of life of the mother and baby, in the short term, is 
undoubtedly enhanced by the birth of a healthy baby as compared to a Rhesus diseased 
infant. Unfortunately, quality of life measures of morbidity associated with Rhesus disease 
do not currently exist, thus, the cost per Rhesus disease avoided cannot be translated into a 
cost per quality adjusted life years (QALYs) measure. 
 
Table 4 lists the baseline parameters used to evaluate the cost-effectiveness of providing 
AADP as a routine antenatal procedure for the different treatment options. The calculations 
are based on a fetal loss rate per woman at risk of 0.04%. An average life expectancy of 74 
years has been assumed which gives a discounted life expectancy of 16.4 years, when 
future years are discounted at 6% per annum.  
 
Table 4 Baseline Parameters for Evaluation of Cost-effectiveness 
 
Sensitisation rate with no AADP  1.5%  
Sensitisation rate with antenatal AADP  0.24% 
Relative risk reduction  84% 
Fetal loss rate per woman at risk under conventional management  0.04% 
Average Life Expectancy   74 years 
Discounted Life Expectancy (6% discount rate)  16.4 
Dosage Regime 2x500 iu 2x1500 iu 
Cost of anti-D IgG £32.86 £31.80 
Cost of Administration  £5 
Economic Savings (discounted at 6% for 3 years)  £1,108 
Median Interval between Pregnancies  35 months 
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The effects of offering AADP to all RhD negative women, or to RhD negative primigravidae 
only, can be modelled by constructing a cohort of women to whom national fertility rates are 
applied. Assuming that fertility patterns are stable, the experience of this cohort over time 
would match the experience of a mixed population of primigravidae and multigravidae during 
any one year.  
 
The most up-to-date data on fertility patterns of women who have completed their 
childbearing are from those born in 1956.
1
 A cohort of 450 such women would eventually 
produce 1,062 deliveries, i.e. the annual number of deliveries in a ‘typical’ district of 500,000 
population accounted for by RhD negative women. Full workings of this method are shown 
in Appendix A. The effectiveness results are shown in Table 5.  
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Table 5 Effectiveness of Treating Rhesus Negative Primigravidae and all Rhesus  
   Negative Women 
 
1. Conventional Management - No Routine Prophylaxis: 
Pregnancy No. No. of RhD 
Negative 
Pregnancies 
No. Sensitised 
for First Time 
in Current 
Pregnancy 
No. of Cases of 
Rhesus 
Disease 
Death Rate 
0.04% No. of 
Fetuses Lost 
First 450 3.90 0.00 0.00 
Second 387 3.33 2.69 0.11 
Third 170 1.44 2.35 0.09 
Subsequent 54 0.45 1.12 0.05 
TOTAL 1,062 9.12 6.16 0.25 
 
2. Prophylaxis to Primigravidae Only, Effective in Current Pregnancy Only: 
Pregnancy No. No. of RhD 
Negative 
Pregnancies 
No. Sensitised 
for First Time 
in Current 
Pregnancy 
No. of Cases of 
Rhesus 
Disease 
Death Rate 
0.04% No. of 
Fetuses Lost 
First 450 0.64 0.00 0.00 
Second 387 3.35 0.44 0.02 
Third 170 1.46 1.37 0.06 
Subsequent 54 0.46 0.81 0.03 
TOTAL 1,062 5.91 2.62 0.11 
 
3. Prophylaxis to all Women, Effective in Each Pregnancy: 
Pregnancy No. No. of RhD 
Negative 
Pregnancies 
No. Sensitised 
for First Time 
in Current 
Pregnancy 
No. of Cases of 
Rhesus 
Disease 
Death Rate 
0.04% No. of 
Fetuses Lost 
First 450 0.64 0.00 0.00 
Second 387 0.55 0.44 0.02 
Third 170 0.24 0.39 0.02 
Subsequent 54 0.08 0.18 0.01 
TOTAL 1,062 1.50 1.01 0.04 
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Note: Full workings are detailed in Appendix A 
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3.3 Cost-effectiveness of Routine Antenatal anti-D Prophylaxis in Primigravidae 
 and all Rhesus Negative Women 
 
The cost-effectiveness outcomes associated with providing routine AADP for RhD negative 
primigravidae and for all RhD negative women are shown in Table 6 for the 2 x 500 iu 
dosage regime with a fetal loss rate of 0.04%. The results relate to treating a cohort of 450 
primagravidae RhD negative women who would, in the course of their life, experience 1,062 
deliveries. Whilst the 2 x 1,250 iu dosage represents a lower cost regime, due to the price of 
the anti-D IgG, the analysis has been based on the higher cost 2 x 500 iu dosage as this 
reflects a conservative view of clinical practice.  
 
Table 6 Results and Cost-effectiveness of Providing Routine Antenatal Treatment  
  for Rhesus Negative Primigravidae and for all Rhesus Negative Women 
 
 Treatment Given to 
Primigravidae Only 
Treatment Given to all 
RhD Negative Women 
Fetal loss rate  in pregnancies at risk 
under conventional management 
 0.04%  0.04% 
Number of sensitisations avoided  3.21  7.62 
Number of cases of Rhesus Disease 
Prevented 
 3.53  5.15 
Number of Fetal Losses Prevented  0.14  0.21 
Number of LYG  2.34  3.41 
   
2 x 500 iu Dosage Regime   
Net Cost  £12,140  £33,064 
Cost per Sensitisation Avoided  £3,782  £4,341 
Cost per case of Rhesus Disease 
Prevented 
 £3,434  £6,420 
Cost per Fetal Loss Prevented  £85,262  £159,383 
Cost per LYG  £5,185  £9,693 
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From Table 6 it is evident that it is much cheaper to treat just primigravidae (net cost 
£12,140) than all RhD negative women (net cost £33,064). Much of this difference is due to 
the number of women being treated under each scenario and, therefore, the total cost of the 
drugs administered. However, when treating all Rhesus negative women more cases of 
Rhesus disease are being prevented, 5.15 compared to 3.54, and, therefore, a greater 
saving due to the avoidance of the treatment costs, which would have been incurred by the 
birth of a baby with Rhesus disease, is being made. 
 
Antenatal anti-D prophylaxis (AADP) would, of course, be non-mandatory were it to become 
a routine procedure. A low uptake rate of the medication would have little effect on the cost-
effectiveness of the procedure. This is because there would be the possibilty of a greater 
number of births affected by HDN and so an increase in costs, but also a reduction in the 
total cost of drugs administered. Moreover, in areas where AADP is a routine procedure, the 
uptake rate is very high.  
 
Both treatment scenarios presented are at a cost-effective level when compared to other 
health care interventions. Cost per LYG is £5,185 and £9,693 and cost per case of Rhesus 
disease prevented is £3,434 and £6,420 when treating primigravidae only and all Rhesus 
negative women respectively. 
 
3.4  Sensitivity Analysis of Cost-effectiveness of Antenatal Anti-D Prophylaxis  
 
3.4.1 The Range of Effectiveness of AADP 
 
In order to estimate  the range of effectiveness of routine AADP, the sensitisation rate for 
the cohort which received antenatal prophylaxis and for the group receiving no treatment 
was varied. The range and the 95% confidence interval for the sensitisation rate, as 
calculated by the meta-analysis in section 2.1.2, was used for the treatment group and the 
control group respectively. The resultant range in cost-effectiveness is given in Table 7. 
 
The cost-effectiveness of routine AADP is not sensitive to the errors in the estimates of 
effectiveness of prophylaxis within the range of estimates obtained from the meta-analysis. 
Of specific note is the stability of the number of fetal losses avoided under the different 
assumptions. 
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Table 7 The Range of Effectiveness of Antenatal Anti-D Prophylaxis 
 
 Sensitisation Rate 
(%) 
95% CI for the Control Group (1.30; 1.65) 
Range for the Antenatal Prophylaxis 
Group 
(0.18; 0.30) 
   
 Treatment Given to 
Primigravidae Only 
Treatment Given to all 
RhD Negative Women 
No. of Sensitisations Avoided (2.61; 3.83) (6.20; 9.09) 
No. of Cases of Rhesus Disease 
Prevented 
(2.88; 4.22) (4.19; 6.15) 
No. of Fetal Losses Prevented (0.14; 0.14) (0.21; 0.21) 
No. of LYG (2.34; 2.35) (3.41; 3.42) 
   
2 x 500 iu Dosage Regime   
Net Cost (£11,188; £13,053) (£31,674; £34,396) 
Cost per Sensitisation Avoided (£2,923; £4,992) (£3,483; £5,551) 
Cost per case of Rhesus Disease 
Prevented 
(£2,650; £4,540) (£5,148; £8,212) 
Cost per Fetal Loss Prevented (£78,743; £91,493) (£152,909; £165,576) 
Cost per LYG (£4,789; £5,564) (£9,299; £10,070) 
 
 
3.4.2 Long-term Savings from AADP   
 
The figure used for the net present value of future savings through the reduction of 
subsequent pregnancies in sensitised women is £1,108 per affected pregnancy. Some of 
the aspects which make up this cost may in fact not be recoverable, e.g. a longer, more 
intensive hospital stay. Therefore, as a worse case scenario, there may be no savings 
achieved. If this were the case, then the absolute gross cost of providing AADP for all 
Rhesus negative women in a ‘typical’ district of 500,000 population is estimated at £40,199 
and £17,037 when providing AADP only for Rhesus negative primigravidae. 
 
However, as discussed in section 3.1, the net present value of savings used as the central 
estimate is likely to be an underestimate of the potential treatment costs. In the absence of 
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any further quantitative information on the likely range of costs, the threshold for the present 
net value of savings, at which routine AADP becomes cost neutral, is tabulated below for 
both treatment groups using the 2 x 500 iu dosage regime. Note that all other parameters 
are set at their baseline values. The amount varies from just over three times to six times 
the baseline estimate.  
 
Table 8 Variation in Savings from AADP 
 
2 x 500 iu Dosage Regime 
Treatment Given to 
Primigravidae Only 
Treatment Given to all 
RhD Negative Women 
Gross Cost of Providing AADP              
(No savings) 
£17,037 £40,199 
   
Original Estimate of Treatment Costs 
Avoided 
£1,108 £1,108 
Threshold for Present Net Value of 
Savings at which AADP becomes Cost 
Neutral 
£3,856 £6,244 
 
 
3.4.3 Variation in Fetal Death Rate 
 
In this evaluation, the baseline fetal death rate after 20 weeks’ gestation due to Rhesus 
disease under conventional management is estimated at 0.04%. However, a death rate of 
0.02% has been quoted in Clarke,
12
 Hussey
13
 and the CESDI report
15
 for fetal loss after 28 
weeks’ gestation. The value of the death rate does not effect the net cost of providing 
AADP, only the cost per fetal life prevented and cost per LYG. The cost per fetal life 
prevented and cost per LYG for a death rate of 0.02%, 50% lower than the base line, and 
0.06%, 50% higher than the base line, is tabulated below for both treatment groups using 
the 2 x 500 iu dosage regime. As can be seen from Table 9, the cost per fetal loss and cost 
per LYG are highly sensitive to variation, especially a reduction, in the fetal loss rate under 
conventional management. 
 
3.4.4 Variation in Discounting Rate 
 
In this evaluation, the potential life years expected for a viable fetus are given equal 
weighting to new born individuals. Fetal loss prior to 20 weeks, though potentially significant, 
has not been included in the analysis. Whilst it is recognised that there is considerable 
controversy over the valuation of different life expectancies,
23
 the uncertainty is addressed in 
 29 
this evaluation by considering a range of different discounting rates applied to the average 
life expectancy of 74 years. This variation in discounting rates has also been applied to the 
value of the direct savings due to the prevention of sensitisations. 
 
Table 9 The Range of Costs of AADP due to Variation in Fetal Death Rate 
 
2 x 500 iu Dosage Regime 
Treatment Given to 
Primigravidae Only 
Treatment Given to all 
RhD Negative Women 
Death rate 0.02%   
 Cost per Fetal Loss Prevented  £170,523  £318,766 
 Cost per LYG  £10,370  £19,386 
   
Death Rate 0.06% 
  
 Cost per Fetal Loss Prevented  £56,841  £106,255 
 Cost per LYG  £3,457  £6,462 
 
 
The baseline analysis uses a discounting rate of 6%, giving a life expectancy of 16.4 years 
and estimated savings of £1,108. Table 10 presents the cost-effectiveness under no 
discounting, giving a life expectancy of 74 years and savings of £1,320, and 10%, giving a 
life expectancy of 10 years and estimated savings of £745. Clearly the cost per LYG is 
highly sensitive to the relative valuation of life expectancy for the unborn fetus. 
 
3.4.5 Variation in the Cost of Implementation of AADP Treatment 
 
It has been envisaged that the anti-D injections can be administered by a midwife at an 
estimated cost of £5 per Rhesus negative woman. However, this was thought to be an 
underestimate by many midwives due to the amount of time it would take them to explain 
clearly all the issues and procedures involved with AADP. Therefore, the cost-effectiveness 
of AADP has been re-calculated for both treatment groups using the 2 x 500 iu dosage 
regime with the cost of implementation of AADP at £10 per Rhesus negative women. Note 
that all other parameters are set at their baseline values. The results are shown in Table 11. 
 
The potential cost-effectiveness of a treatment programme is sensitive to large increases in 
the logistic costs of administration. Appendix 2 discribes a simple, yet effective, strategy of 
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implementing an antenatal anti-D treatment programme which has been carried out 
successfully in Southern Derbyshire Health Authority. 
Table 10 The Range of Costs of AADP under Different Discounting Rates 
 
2 x 500 iu Dosage Regime 
Treatment Given to 
Primigravidae Only 
Treatment Given to all 
RhD Negative Women 
10% Discount Rate   
 Net Cost  £13,745  £35,402 
 Cost per Sensitisation Avoided  £4,282  £4,648 
 Cost per case of Rhesus 
Disease Prevented 
 £3,888  £6,874 
    
 Cost per Fetal Loss Prevented  £96,533  £170,654 
 Cost per LYG  £9,662  £17,080 
   
0% Discount Rate   
 Net Cost  £11,204  £31,701 
 Cost per Sensitisation Avoided  £3,491  £4,162 
 Cost per case of Rhesus 
Disease Prevented 
 £3,170  £6,155 
    
 Cost per Fetal Loss Prevented  £78,692  £152,813 
 Cost per LYG  £1,063  £2,065 
 
 
Table 11 The Range of Costs of AADP due to Variation in Implementation Costs 
 
2 x 500 iu Dosage Regime 
Treatment Given to 
Primigravidae Only 
Treatment Given to all 
RhD Negative women 
Net Cost  £14,390  £38,372 
Cost per Sensitisation Avoided  £4,483  £5,038 
Cost per case of Rhesus Disease 
Prevented 
 £4,071  £7,451 
   
Cost per Fetal Loss Prevented  £101,064   £184,974 
Cost per LYG  £6,146  £11,249 
 
 
3.4.6 Variation in the Costs of anti-D Immunoglobulin 
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As anti-D Immunoglobulin is a human-derived blood product, there are important issues of 
safety and the likelihood of contracting infections to consider with the introduction of routine 
AADP. At present, human plasma is the only source of therapeutic IgG and is priced by BPL 
at £16.43 per 500 iu vial. At the time of writing BPL has given assurance of the stability of 
the cost of its IgG. 
 
For the sake of safety, monoclonal anti-D is under development and is considered to be a 
safer option than human plasma, were it to become available for routine use. The cost of 
monoclonal anti-D is not known, but it could be considerably more expensive than IgG taken 
from human donors. 
 
Figure 5 shows the net cost of AADP for both treatment groups using the 2 x 500 iu regime 
for a ‘typical’ district of 500,000 population, when increasing the cost of IgG up to ten times 
the present cost. All the other parameters which affect the cost of AADP are set at their 
baseline values. 
 
The baseline cost-effectiveness of routine AADP is just over £30,000 per LYG when the 
cost of the anti-D Immunoglobulin is three times the present cost. 
 
Figure 5 The Effect of Varying the Cost of Anti-D Immunoglobulin on the Net Cost of 
   AADP 
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3.4.7 Worst Case Scenario: Variation of all Baseline Parameters 
 
In order to create a worst case scenario for the cost-effectiveness outcomes associated with 
providing routine AADP, all baseline parameters have been varied at once. This has meant 
varying the rate of sensitisation for the treatment and no treatment groups in order to 
calculate a range of costs, setting the discounting rate at 10%, the fetal death rate at 0.02%, 
the cost of implementation of AADP at £10 and assuming no savings are achieved by the 
reduction of subsequent pregnancies in sensitised women. The cost of the IgG was not 
varied as this is a known fixed value. Table 12 presents the cost-effectiveness under these 
variations for both treatment groups using the 2 x 500 iu dosage regime. 
 
The net cost for treating all Rhesus negative women in the worst case scenario is £45,507, 
compared to the original net cost of £33,064, an increase of £12,443. This is equivalent to 
£8,836 (£7,396; £10,865) per case of Rhesus disease prevented, compared to £6,420 
(£5,148; £8,212) as calculated before. Even in the worst case scenario, the range of the 
costs per case of Rhesus disease prevented overlaps with the range originally calculated as 
shown in Table 7. 
 
Table 12 The Range of Costs of AADP due to Variation of all Baseline Parameters 
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2 x 500 iu Dosage Regime 
Treatment Given to 
Primigravidae Only 
Treatment Given to all 
RhD Negative Women 
Net Cost £19,287 £45,507 
 - Range (£19,287; £19,287) (£45,507; £45,507) 
Cost per Sensitisation Avoided £6,009 £5,975 
 - Range (£5,038; £7,376) (£5,004; £7,344) 
Cost per case of Rhesus Disease Prevented £5,456 £8,836 
 - Range (£4,568; £6707) (£7,396; £10,865) 
Cost per Fetal Loss Prevented £19,287 £438,737 
 - Range (£19,287; £19,287) (£438,128; £439,383) 
Cost per LYG £27,115 £43,912 
 - Range (£27,173; £27,060) (£43,851; £43,976) 
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3.5 Conclusion on Cost-effectiveness 
 
The total annual gross cost to a ‘typical’ health authority when treating all Rhesus negative 
women is estimated to be in the region of £35,000. However, it should be recognised that 
the potential benefits to be derived are also small. 
 
Such a health authority may expect to prevent one fetal loss approximately every seven 
years under a primagavidae only policy and every five years under a policy to treat all 
Rhesus negative mothers; probably more important is the role of routine prophylaxis in 
preventing treatable Rhesus disease. 
 
As discussed in Section 2, the treatment has been shown to be effective in reducing 
sensitisation. The cost-effectiveness is sensitive to: 
 
 the cost of treating pregnant women who are found to have been sensitised in an earlier 
pregnancy; 
 assumptions regarding the relationship between sensitisation and fetal loss; 
 the valuation of fetal loss in terms of LYGs; 
 errors in estimating the actual fetal loss rate under conventional management. 
 
Overall, the cost-effectiveness under the baseline assumptions compares favourably with 
other treatments which are currently funded. For example, the use of ‘statins’ in the 
secondary prevention of coronary heart disease has a cost per LYG of £5,100 and 
haemodialysis for end-stage renal failure, which is widely recognised as a high cost 
intervention, has a cost per LYG of more than £20,000. Furthermore, the sensitivity analysis 
undertaken indicates that the estimated cost-effectiveness is robust in relation to these 
comparator treatments. 
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4. OPTIONS FOR PURCHASERS AND PROVIDERS 
 
Two questions have been considered in this report: 
 
a)  Who to provide antenatal prophylaxis for?  
b) What regime of anti-D to administer? 
  
As there was no firm evidence to the contrary, this report has assumed that there is no 
difference in effectiveness between dosage regimes which are currently considered to be 
appropriate. Thus, at the time of writing, as the 1,250 iu treatment option was cheaper, this 
is the dosage regime recommended. However, the cost differential between the two regimes 
is small and if the cost or availability were to change, then so too would the advice.  
 
The options considered in respect of the first question are as follows: 
 
Option 1 Do not provide anti-D prophylaxis as a routine antenatal procedure. 
Option 2 Provide anti-D prophylaxis as a routine antenatal procedure for Rhesus negative  
  primigravidae only. 
Option 3 Provide anti-D prophylaxis as a routine antenatal procedure for all Rhesus   
  negative women regardless of the number of previous pregnancies. 
 
Both options 2 and 3 provide low-cost and cost-effective strateges for preventing HDN. 
Option 2, which is restricting the provision of routine AADP to primigravidae, has a lower 
gross cost and is marginally more cost-effective in comparison to option 3. However, 
practical and ethical difficulties are foreseen in the implementation of option 2, and thus, 
since option 3 is cost-effective in comparison to conventional management, this is the 
preferred option.  
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5.  DISCUSSION AND CONCLUSIONS 
 
5.1 Implementing a Policy of Routine Antenatal Anti-D Prophylaxis 
 
Considering the practicalities of routine administration of anti-D in Sheffield, the following 
points were made by local community midwives: 
 
 That women are, in general, unaware of what anti-D is and that it is a blood product. If 
prescribed, there would be a definite need to supply women with more information about 
routine administration of anti-D, why it was recommended and if administration would 
pose any risk to the women’s own health. The supplier of anti-D should ideally provide 
written information about its product and an assurance against the likelihood of 
contracting infections from the specimen, in particular, Creutzfeldt-Jakob Disease (CJD), 
Acquired Immune Deficiency Syndrome (AIDS) and hepatitis. 
 
 Women should be encouraged to exercise their choice of having antenatal anti-D 
routinely or only as a result of the currently recognised sensitisation events, i.e. 
abdominal trauma, abortion, amniocentesis, chorion villous sampling, antepartum 
haemorrhage, external aphalalic version and termination of pregnancy. Information 
should be available to women to support such a decision. 
 
 The demand for anti-D for routine administration to antenatal women could technically 
exceed the current supply. 
 
 At present, it is not clear who is incurring the cost of supplying anti-D for routine 
administration to Rhesus negative women. Either the local maternity hospital pharmacy 
department or the women’s general practitioners could incur the expense. 
 
5.2 Information to Patients 
 
Anti-D Immunoglobulin is a human plasma-based product and so, naturally, there is concern 
over its safety. Intramuscular immunoglobulins, which include anti-D, have an excellent 
safety record with no reported cases of viral transmission. Moreover, the available products 
are produced from non-UK donor plasma and the Medicines Control Agency has 
recommended these for antenatal prophylaxis. Patients and staff ought already to be 
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receiving suitable information about the safety of anti-D IgG, as postnatal anti-D prophylaxis 
is a routine procedure. 
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APPENDIX A The Full Workings to Calculate the Results of Treating All 
Rhesus Negative Women and Rhesus Negative 
Primigravidae 
 
Complications due to sensitisation of the mother only occur in subsequent Rhesus positive 
pregnancies. In order to achieve the treatment of 1,062 pregnancies, a cohort of 450 
Rhesus negative primigravidae need to be considered. This is calculated as shown in Table 
1 which shows the results for all Rhesus negative women. Table 2 shows the results for 
Rhesus primigravidae. The method of calculation when no antenatal prophylaxis is given is 
as follows: 
 
The number of Rhesus negative pregnancies treated in each pregnancy [Table 1 - Col. B] is 
the number in the previous pregnancy multiplied by the percentage going on to a further 
pregnancy: i.e. B3 = B2 x H2. Therefore, the total number of Rhesus negative pregnancies 
treated is just the sum of these and totals the 1,062 pregnancies in a ‘typical’ district. 
 
450 non-sensitised Rhesus negative women have a first pregnancy, [C1]. Of these, 59%, 
[D1], will have a Rhesus positive baby and, therefore, their pregnancy will be at risk. This 
results in 266 pregnancies at risk, [E1]. In the case described, the mothers are not given 
antenatal prophylaxis and, therefore, 1.5%, [F1], will become sensitised. This results in 3.90 
sensitisations, [G1]. Of these women, 86% will go on to have a second pregnancy, [H1], of 
which 80% of these second pregnancies, [J2], will be Rhesus positive and with an affected 
fetus. This results in 2.69 cases of Rhesus disease, [K2].  
 
This cycle is then repeated. The number of non-sensitised Rhesus negative women entering 
a second pregnancy, [C2], is the original number of non-sensitised women, [C1], minus the 
prevalent number of women sensitised during earlier pregnancies, [N1], multiplied by 86%, 
[H1], the percentage of women having a second pregnancy. This results in 384 non-
sensitised Rhesus negative women entering a second pregnancy, [C2]. Of these, 59%, [D2], 
will have a Rhesus positive baby and, therefore, their pregnancy will be at risk. This results 
in 226 pregnancies at risk, [E2]. As no prophylaxis is given, 1.5%, [F2], of these will become 
sensitised for the first time, i.e. 3.33 sensitisations, [G2]. The number of sensitised women 
going on to a further pregnancy is recorded in column I. The number entering a third 
pregnancy equals the number sensitised for the first time in the second pregnancy, [G2], 
plus the number sensitised in the first pregnancy who continued on to a second pregnancy, 
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[I2], multiplied by 0.44, [H2], the percentage of women having a third pregnancy. Of these 
fetuses, 80% will be Rhesus positive and, therefore, will be affected This results in 2.35 
cases of Rhesus disease, [K3].  
 
This process is then repeated again and continues exactly as described, but the percentage 
of women entering a fourth and subsequent pregnancy reduces to 32%, [H3].  
 
This method of calculation has been used for all scenarios, so in the case where antenatal 
prophylaxis is administered, the sensitisation rate reduces to 0.24%, [F6], instead of 1.5%, 
[F1]. In the scenario of just treating primigravidae, only the first 450 pregnancies are given 
antenatal prophylaxis and, therefore, the risk of sensitisation in second and subsequent 
pregnancies returns to 1.5%.  
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Appendix A   Table 1  Results of Treating all Rhesus Negative Women 
 
1. Treatment - No Prophylaxis 
A B C D E F G H I J K L M 
Pregnancy No. No. of Rh 
Negative 
Pregnancies 
No. of 
Non-
Sensitised 
RhD 
Negative 
Proportion of 
Women who 
will have a 
RhD Positive 
Baby (i.e. at 
risk) 
No. at 
Risk 
Sensitisation 
Rate 
No 
Sensitised 
for First 
Time in 
Current 
Pregnancy 
Proportion 
Proceeding 
to Next 
Pregnancy 
No. 
Sensitised 
from 
Previous 
Pregnancies 
Risk of Rh Positive 
Fetus in Current 
Pregnancy Having 
Been Sensitised in 
Previous 
Pregnancy 
No. of 
Cases 
of 
Rhesus 
Disease 
Death 
Rate 
0.04% 
No. of 
Fetuses 
Lost 
Prevalent No. 
of Sensitised 
Women 
During Each 
Pregnancy 
1.  First 450 450 0.59 266 1.5% 3.90 0.86 0.00 0.00 0.00 0.00 3.90 
2.  Second 387 384 0.59 226 1.5% 3.33 0.44 3.36 0.80 2.69 0.108 6.68 
3.  Third 170 166 0.59 98 1.5% 1.44 0.32 2.94 0.80 2.35 0.095 4.38 
4.  Subsequent 54 52 0.59 30 1.5% 0.45  1.40 0.80 1.12 0.045 1.85 
5.  TOTAL 1,062 1,051  620  9.12  7.70  6.16 0.25 16.82 
 
2. Treatment - Prophylaxis to All Women, 84% Effective in Each Pregnancy 
Pregnancy No. No. of Rh 
Negative 
Pregnancies 
No. of 
Non-
Sensitised 
RhD 
Negative 
Proportion of 
Women who 
will have a 
RhD Positive 
Baby (i.e. at 
risk) 
No. at 
Risk 
Sensitisation 
Rate 
No 
Sensitised 
for First 
Time in 
Current 
Pregnancy 
Proportion 
Proceeding 
to Next 
Pregnancy 
No. 
Sensitised 
from 
Previous 
Pregnancies 
Risk of Rh Positive 
Fetus in Current 
Pregnancy Having 
Been Sensitised in 
Previous 
Pregnancy 
No. of 
Cases 
of 
Rhesus 
Disease 
Death 
Rate 
0.04% 
No. of 
Fetuses 
Lost 
Prevalent No. 
of Sensitised 
Women 
During Each 
Pregnancy 
6.  First 450 450 0.59 266 0.24% 0.64 0.86 0.00 0.00 0.00 0.00 0.64 
7.  Second 387 386 0.59 228 0.24% 0.55 0.44 0.55 0.80 0.44 0.02 1.10 
8.  Third 170 170 0.59 100 0.24% 0.24 0.32 0.48 0.80 0.39 0.02 0.72 
9.  Subsequent 54 54 0.59 32 0.24% 0.08  0.23 0.80 0.18 0.01 0.31 
10.  TOTAL 1,062 1,060  625  1.50  1.26  1.01 0.04 2.76 
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Appendix A  Table 2 Results of Treating Rhesus Negative Primigravidae 
1. No Prophylaxis 
A B C D E F G H I J K L M 
Pregnancy No. No. of Rh 
Negative 
Pregnancies 
No. of Non-
Sensitised 
RhD 
Negative 
Proportion of 
Women who 
will have a 
RhD Positive 
Baby (i.e. at 
risk) 
No. at 
Risk 
Sensitisation 
Rate 
No 
Sensitised 
for First 
Time in 
Current 
Pregnancy 
Proportion 
Proceeding 
to Next 
Pregnancy 
No. 
Sensitised 
from 
Previous 
Pregnancies 
Risk of Rh Positive 
Fetus in Current 
Pregnancy Having 
Been Sensitised in 
Previous 
Pregnancy 
No. of 
Cases 
of 
Rhesus 
Disease 
Death 
Rate 
0.04% 
No. of 
Fetuses 
Lost 
Prevalent No. 
of Sensitised 
Women 
During Each 
Pregnancy 
1.  First 450 450 0.59 266 1.5% 3.98 0.86 0.00 0.00 0.00 0.00 3.98 
2.  Second 387 384 0.59 228 1.5% 3.39 0.44 2.42 0.80 2.74 0.11 6.82 
3.  Third 170 166 0.59 100 1.5% 1.47 0.32 3.00 0.80 2.40 0.09 4.47 
4.  Subsequent 54 52 0.59 30 1.5% 0.46  1.43 0.80 1.14 0.05 1.89 
5.  TOTAL 1,062 1,051  620  9.30  7.86  6.28 0.25 17.16 
 
2. Prophylaxis to Primigravidae Only, 84% Effective in Current Pregnancy Only 
Pregnancy No. No. of Rh 
Negative 
Pregnancies 
No. of 
Non-
Sensitised 
RhD 
Negative 
Proportion of 
Women who 
will have a 
RhD Positive 
Baby (i.e. at 
risk) 
No. at 
Risk 
Sensitisation 
Rate 
No 
Sensitised 
for First 
Time in 
Current 
Pregnancy 
Proportion 
Proceeding 
to Next 
Pregnancy 
No. 
Sensitised 
from 
Previous 
Pregnancies 
Risk of Rh Positive 
Fetus in Current 
Pregnancy Having 
Been Sensitised in 
Previous 
Pregnancy 
No. of 
Cases 
of 
Rhesus 
Disease 
Death 
Rate 
0.04% 
No. of 
Fetuses 
Lost 
Prevalent No. 
of Sensitised 
Women 
During Each 
Pregnancy 
6.  First 450 450 0.59 266 0.24% 0.64 0.86 0.00 0.00 0.00 0.00 0.64 
7.  Second 387 386 0.59 228 1.5% 3.35 0.44 0.55 0.80 0.44 0.02 3.90 
8.  Third 170 168 0.59 99 1.5% 1.46 0.32 1.72 0.80 1.37 0.06 3.18 
9.  Subsequent 54 53 0.59 31 1.5% 0.46  1.02 0.80 0.81 0.03 1.47 
10.  TOTAL 1,062 1,058  624  5.91  3.28  2.66 0.11 9.19 
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APPENDIX B Antenatal Anti-D Prophylaxis Treatment - It Does Work in   
 Practice 
 
In Southern Derbyshire health district a routine antenatal anti-D prophylaxis treatment 
programme has been implemented successfully. Before the programme began, the rate of 
sensitisation in Rhesus negative women was 1.12%, (1988 - 90), whereas during 1993 - 95, 
the earliest date at which any effects of the programme might be detected, the rate had 
reduced to 0.28%
a
. 
 
Women who need prophylaxis are identified by hospital staff, general practitioners and 
community midwives, and a record of them is kept in a specific diary. The anti-D 
Immunoglobulin is stored at Derby City General Hospital Blood Bank. Where each week, a 
clerk looks in the diary and dispatches the anti-D to the appropriate general practice surgery 
or community clinic for the women needing treatment that week. The shelf life of the anti-D 
Immunoglobulin is stated to be two years. The clerical work takes about an hour each week. 
The anti-D is delivered to the appropriate centre by the routine van run and the delivery of 
the anti-D Immunoglobulin is, therefore, at no extra cost to the health authority. The 
packages are addressed to the midwives and treatment is given at 28 and 34 weeks’ 
gestation  during a normal routine visit. Confirmation of dosage is then returned to the clerk. 
 
In Southern Derbyshire, the  cost of the prophylaxis has been estimated at around £30 per 
pregnancy and the overall cost is about £15,000 per annum. The major expense of the 
programme is the anti-D Immunoglobulin. The time taken by the clerk and the midwife also 
contributes to the cost, but this is not considered to be a major factor. This treatment 
programme was originally implemented for primigravidae only, but with extra funding it was 
extended to cover all Rhesus negative women. 
                                                 
a
  Mayne S, Parker JH, Harden TA, et al. Rate of RhD sensitisation before and after 
implementation of a community based antenatal prophylaxis programme. British Medical 
1997; 315:1588. 
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below:- 
 
Guidance Notes for Purchasers  
 
96/01 Working Group on Acute Purchasing: The Use of DNase in Cystic Fibrosis (1996)  £6.00 
 by JN Payne, S Dixon, NJ Cooper and CJ McCabe.  
       
96/02 Working Group on Acute Purchasing: Tertiary Cardiology (1996)    £6.00 
 by J Tomlinson, J Sutton and CJ McCabe.  
  
96/03 Working Group on Acute Purchasing: The Use of Cochlear Implantation (1996) £6.00 
 by Q Summerfield and J Tomlinson.  
  
96/04 Working Group on Acute Purchasing: Statin Therapy / HMG Co-A     
  Reductase Inhibitor Treatment in the Prevention of Coronary Heart Disease 
£6.00 
 (1996) by MD Pickin, JN Payne, IU Haq, CJ McCabe, SE Ward, PR Jackson  
 and WW Yeo.  
  
97/01 Working Group on Acute Purchasing: The Clinical and Cost-effectiveness   £10.00 
 of Computed Tomography in the Management of Transient Ischaemic   
 Attack and Stroke (1997) by A Ferguson and CJ McCabe.  
  
97/02 Working Group on Acute Purchasing: Prostacyclin in the Treatment of    £10.00 
 Primary Pulmonary Hypertension (1997) by TW Higenbottam, SE Ward,   
 A Brennan, CJ McCabe, RG Richards and MD Stevenson.  
  
97/03 Working Group on Acute Purchasing: The Use of Riluzole in the Treatment £10.00 
 of Amyotrophic Lateral Sclerosis (Motor Neurone Disease) (1997) by J Chilcott,  
 P Golightly, D Jefferson, CJ McCabe and S Walters. 
 
  
97/04 Working Group on Acute Purchasing: Recombinant Factor VIII Versus    £10.00 
 Plasma Derived Factor VIII in the Management of Haemophilia A: An   
 Examination of the Costs and Consequences (1997) by C Green and   
 RL Akehurst.  
  
97/05 Working Group on Acute Purchasing: The Use of Cisplatin and Paclitaxel £10.00 
 as a First Line Treatment in Ovarian Cancer (1997) by SM Beard, R Coleman,   
 J Radford and J Tidy.  
  
97/06 Working Group on Acute Purchasing: The Use of Alpha Interferon in the    
 Management of Chronic Myeloid Leukaemia (1997) by RG Richards and  
£10.00 
 CJ McCabe.  
  
97/07 Working Group on Acute Purchasing: Spinal Cord Stimulation in the    £10.00 
 Management of Chronic Pain (1997) by J Tomlinson, CJ McCabe and B Collett.  
  
97/08 Working Group on Acute Purchasing: The Use of Growth Hormone in Adults   £5.00 
 (1997) by JN Payne and RG Richards.  
  
97/09 Working Group on Acute Purchasing: A Review of the Use of Donepezil in the   £10.00 
 Treatment of Alzheimer’s Disease (1997) by FA Pitt, J Chilcott, P Golightly,   
 J Sykes, M Whittingham.  
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97/10 Working Group on Acute Purchasing: The Use of Bone Anchored Hearing Aids   
 
£10.00 
 (1997) by NJ Cooper, J Tomlinson and J Sutton.  
  
98/01 Working Group on Acute Purchasing: A Review of the Use of Current Atypical  
 Antipsychotics in the Treatment of Schizophrenia (1998) by S Beard, J Brewin,  
 C Packham, P Rowlands, P Golightly. 
£10.00 
  
98/02 Working Group on Acute Purchasing: Internal Fixation of Tibial Shaft and   
 Distal Radius Fractures in Adults (1998) by N Calvert, P Triffit, S Johnstone,  
 RG Richards. 
£10.00 
  
98/03 Working Group on Acute Purchasing: Tacrolimus and Mycophenolate Mofetil as 
 Maintenance Immunosuppressants following Renal Transplantation (1998) by  
 J Chilcott, M Corchoran, K Rigg, R Burden. 
£10.00 
 
98/04 Working Group on Acute Purchasing: The Effectiveness of High Dose 
Chemotherapy and Autologous Stem Cell Transplantation in the Treatment of 
Non-Hodgkin’s Lymphoma and Hodgkin’s Disease (1998) by S Beard, P Lorigan, 
A Simms, F Sampson. 
 
£10.00 
 
98/05 Working Group on Acute Purchasing:  Angiotensin-Converting Enzyme (ACE) 
Inhibitors in Heart Failure: Reducing Mortality and Costs to the NHS (1998) by  
N Calvert, J Cornell, C Singleton. 
 
 
£10.00 
98/06 Working Group on Acute Purchasing: The Use Of Ultrasound (Viability) Scans In 
Early Pregnancy Bleeding (1998) by N Calvert, C Singleton, P Tromans. 
 
£10.00 
98/07 Working Group on Acute Purchasing: Surgery for Epilepsy (1998) by J Chilcott,  
C Richards, A Kemeny, S Howell. 
 
£10.00 
98/08 Working Group on Acute Purchasing: The Effectiveness of High Dose 
Chemotherapy with Autologous Stem Cell / Bone Marrow Transplantation in the 
Treatment of Multiple Myeloma (1998) by S Beard, F Sampson, E Vandenberghe 
and F Scott. 
 
£10.00 
98/09 Working Group on Acute Purchasing: Magnetic Resonance Imaging (MRI) in the 
Management of the Knee (1998) by S Beard and I Perez. 
 
£10.00 
98/10 Working Group on Acute Purchasing: Supplementary Document: The Use of 
Paclitaxel in the First Line Treatment of Ovarian Cancer (1998) by S Beard, 
 R Coleman, J Radford and J Tidy. 
 
£10.00 
98/11 Working Group on Acute Purchasing: The use of Fluoridated School Milk in the 
Prevention of Dental Caries (1998) by N Calvert and N Thomas. 
 
£10.00 
99/01 Working Group on Acute Purchasing: The Role of Leukotriene Inhibitors in 
Asthma (1999) by M Stevenson, R Richards, S Beard. 
 
£15.00 
99/02 Working Group on Acute Purchasing: Partial Hepatectomy for Liver Metastases 
(1999) by S Beard, M Holmes, A Majeed, C Price. 
£15.00 
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99/03 Working Group on Acute Purchasing: A review of the Use of Propentofylline in the 
Treatment of Dementia (1999) by J Chilcott, K Perrett, P Golightly, J Sykes and  
M Whittingham. 
 
£15.00 
  
 
Discussion Papers 
 
  
No. 1. Patients with Minor Injuries: A Literature Review of Options for their    £7.00 
 Treatment Outside Major Accident and Emergency Departments   
 or Occupational Health Settings (1994) by S Read.       
  
96/01  Working Group on Acute Purchasing: The Role of Beta Interferon    £7.50 
 in the Treatment of Multiple Sclerosis (1996) by RG Richards,   
 CJ McCabe, NJ Cooper, SF Paisley, A Brennan and RL Akehurst.   
  
96/02 The Mid-level Practitioner: A Review of the Literature on Nurse Practitioner   £10.00 
 and Physician Assistant Programmes (1996) by P Watson, N Hendey,   
 R Dingwall, E Spencer and P Wilson.    
  
96/03 Evaluation of two Pharmaceutical Care Programmes for People with   £10.00 
 Mental Health Problems Living in the Community (1996) by A Aldridge,     
 R Dingwall and P Watson.          
  
97/01 Working Group on Primary and Community Care Purchasing : Report of   £10.00 
 the Sub-Group on the Promotion of Quality in Primary Care - Effective  
 Purchasing of Primary and Community Health Care: Promotion of Quality in   
 the Provision of Primary Care (1997) by S Jennings and M Pringle.  
  
97/02 Working Group on Primary and Community Care Purchasing : Report of   £10.00 
 the Sub-Group on Information Needs for Health Needs Assessment and   
 Resource Allocation (1997) by T Baxter, A Howe, C Kenny, D Meechan,   
 M Pringle, P Redgrave, J Robinson and  A Sims.  
  
98/01 Working Group on Primary and Community Care Purchasing : Hospital at Home - 
Lessons from Trent (1998) by I Perez, A Wilson, A Sims and R Harper. 
£10.00 
 
 
Copies of these documents are available from:- 
 
Alison Ring 
Information Resources 
Trent Institute for Health Services Research 
Regent Court 
30 Regent Street 
SHEFFIELD S1 4DA 
 
Tel  0114 222 0703  
Fax 0114 272 4095 
E-mail scharrlib@sheffield.ac.uk 
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Please make cheques payable to “The University of Sheffield” 
 
